Application of Proteomics in Alzheimer’s Disease: A Mini Review

Author:

Sukumaran Pariveena,Bahardin Ainun Aida,Abdul Razak Luqmanul Hakim,Senik Mohd Harizal

Abstract

Alzheimer’s disease (AD) is classified as one of neurodegenerative disease caused by neuronal death. It is characterized as memory impairment, including the inability to produce new memories. Since AD has low treatment effectiveness, proteomics research opens possibilities for advancement. Proteomics is the study of proteomes produced by the disease-bearing host to identify and understand diseases. In this case, to investigate the use of protein as a reliable molecular entity and their involvement in AD. Therefore, this review focused on three main applications of proteomics; the potential use of proteomics as a diagnostic tool for AD, the use of proteomics to assess the treatment progression of AD and the advancement in AD research. The review discussed three research areas utilizing the proteomics approach: ageing, behavioural, and demographic research of AD populations. Proteomic approaches have also been shown to be effective to discover the biomarkers for infectious diseases, cancers, heart diseases, and neurological disorders. Although much work remained to be done, the proteomics approach is an interesting method to be carried out in detecting AD at an earlier stage and will be very useful for AD treatment and management in the future.

Publisher

Universiti Putra Malaysia

Subject

General Medicine

Reference108 articles.

1. 1. Moujalled, D., Strasser, A., & Liddell, J. R. (2021). Molecular mechanisms of cell death in neurological diseases. Cell Death & Differentiation 2021 28:7, 28(7), 2029–2044. doi:10.1038/s41418-021-00814-y

2. 2. Pang, S. Y. Y., Teo, K. C., Hsu, J. S., Chang, R. S. K., Li, M., Sham, P. C., & Ho, S. L. (2017). The role of gene variants in the pathogenesis of neurodegenerative disorders as revealed by next generation sequencing studies: A review. Translational Neurodegeneration, 6(1), 1–11. doi:10.1186/S40035-017-0098-0/TABLES/3

3. 3. Nuri, T. H. M., Hong, Y. H., Ming, L. C., Joffry, S. M., Othman, M. F., & Neoh, C. F. (2017). Knowledge on Alzheimer’s Disease among Public Hospitals and Health Clinics Pharmacists in the State of Selangor, Malaysia. Frontiers in Pharmacology, 8(OCT), 739. doi:10.3389/FPHAR.2017.00739

4. 4. Magalingam, K. B., Radhakrishnan, A., Ping, N. S., & Haleagrahara, N. (2018). Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s Disease. BioMed Research International, 2018. doi:10.1155/2018/3740461

5. 5. Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., Awasthi, A., Barker-Collo, S. L., Baune, B. T., Béjot, Y., Belachew, A. B., Bennett, D. A., Biadgo, B., Bijani, A., Bin Sayeed, M. S., … Murray, C. J. L. (2019). Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(1), 88–106. doi:10.1016/S1474-4422(18)30403-4

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3